Copy Link Print Information

Agrin Protein, Human (CHO, His)

3 Cited Publications
Customer Review

Based on 3 publication(s) in Google Scholar

Agrin is critical for neuromuscular junction development and was discovered in mouse knockout studies. It contains laminin G, Kazal-type serpin, and epidermal growth factor domains. Agrin Protein, Human (CHO, His) is the recombinant human-derived Agrin protein, expressed by CHO , with N-6*His labeled tag.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: CHO
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Experimental Validation Results for Agrin Protein, Human (CHO, His)
  • Experimental Validation Results for Agrin Protein, Human (CHO, His)
  • Agrin Protein, Human (CHO, His) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Biological Activity

Description

Agrin is critical for neuromuscular junction development and was discovered in mouse knockout studies. It contains laminin G, Kazal-type serpin, and epidermal growth factor domains. Agrin Protein, Human (CHO, His) is the recombinant human-derived Agrin protein, expressed by CHO , with N-6*His labeled tag.

Background

The Agrin protein, an essential component in the development of the neuromuscular junction (NMJ), has been identified through knockout studies in mice. It encompasses laminin G, Kazal type serine protease inhibitor, and epidermal growth factor domains. Additionally, post-translational modifications occur, including the addition of glycosaminoglycans and disulfide bonds. Notably, a mutation in this gene has been associated with congenital myasthenic syndrome affecting limb-girdle muscles in a specific family. Alternative splicing gives rise to multiple transcript variants that encode different isoforms. This protein exhibits a broad expression pattern, with notable presence in kidney, lung, and 21 other tissues.

Verified Bioactivity

Measured by the ability of the immobilized protein to support the adhesion of U-87 MG human glioblastoma/astrocytoma cells. The ED50 this effect is <113.4 ng/mL after 1 hour incubation at 37 °C, corresponding to a specific activity is > 8.8183×103 units/mg.

MCE Validation Data

  • Purity - SDS-PAGE

    Purity - SDS-PAGE

    ≥ 95%, as determined by reducing SDS-PAGE.

  • Bioactivity - Cell-Based Assay

    Bioactivity - Cell-Based Assay

    Measured by the ability of the immobilized protein to support the adhesion of U‑87 MG human glioblastoma/astrocytoma cells. The ED50 for this effect is 113.4 ng/mL after 1 hour incubation at 37 °C, corresponding to a specific activity is > 8.8183×103 units/mg.

Technical Parameters

  • Species Human
  • Source CHO
  • Tag N-6*His
  • Accession

    O00468-6/NP_940978 (A1260-P2045)

  • Gene ID
    375790  [NCBI]
  • Molecular Construction
    • N-term
    • 6*His
    • Agrin (A1260-P2045)
      Accession # O00468-6/NP_940978
    • C-term
  • Protein Length

    Partial

  • Synonyms

    AGRN; AGRN Protein; Prev. AGRIN; CMS8; Agrin Proteoglycan; Agrin; CMSPPD

  • AA Sequence

    ATSGAIAAGATARATTASRLPSSAVTPRAPHPSHTSQPVAKTTAAPTTRRPPTTAPSRVPGRRPPAPQQPPKPCDSQPCFHGGTCQDWALGGGFTCSCPAGRGGAVCEKVLGAPVPAFEGRSFLAFPTLRAYHTLRLALEFRALEPQGLLLYNGNARGKDFLALALLDGRVQLRFDTGSGPAVLTSAVPVEPGQWHRLELSRHWRRGTLSVDGETPVLGESPSGTDGLNLDTDLFVGGVPEDQAAVALERTFVGAGLRGCIRLLDVNNQRLELGIGPGAATRGSGVGECGDHPCLPNPCHGGAPCQNLEAGRFHCQCPPGRVGPTCADEKSPCQPNPCHGAAPCRVLPEGGAQCECPLGREGTFCQTASGQDGSGPFLADFNGFSHLELRGLHTFARDLGEKMALEVVFLARGPSGLLLYNGQKTDGKGDFVSLALRDRRLEFRYDLGKGAAVIRSREPVTLGAWTRVSLERNGRKGALRVGDGPRVLGESPVPHTVLNLKEPLYVGGAPDFSKLARAAAVSSGFDGAIQLVSLGGRQLLTPEHVLRQVDVTSFAGHPCTRASGHPCLNGASCVPREAAYVCLCPGGFSGPHCEKGLVEKSAGDVDTLAFDGRTFVEYLNAVTESEKALQSNHFELSLRTEATQGLVLWSGKATERADYVALAIVDGHLQLSYNLGSQPVVLRSTVPVNTNRWLRVVAHREQREGSLQVGNEAPVTGSSPLGATQLDTDGALWLGGLPELPVGPALPKAYGTGFVGCLRDVVVGRHPLHLLEDAVTKPELRPCPTP

  • Molecular Weight

    Approximately 100-110 kDa, based on SDS-PAGE under reducing conditions.

  • Glycosylation

    Yes

  • Purity

    ≥ 95%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder.

Formulation

Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

Assay Types
  • 1/16

    MedChemExpress Validation
     ≥ 95%, as determined by reducing SDS-PAGE.

  • 1/16

    MedChemExpress Validation
     Measured by the ability of the immobilized protein to support the adhesion of U‑87 MG human glioblastoma/astrocytoma cells. The ED50 for this effect is 113.4 ng/mL after 1 hour incubation at 37 °C, corresponding to a specific activity is > 8.8183×103 units/mg.

  • Agrin Protein, Human (CHO, His) Product Image
    1/16
  • Experimental Validation Results for Agrin Protein, Human (CHO, His)
  • Experimental Validation Results for Agrin Protein, Human (CHO, His)
  • Agrin Protein, Human (CHO, His) Product Image